LNCR3
MCID: LNG064
MIFTS: 70

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 57 13 71
Lung Adenocarcinoma 12 20 29 6 15 17
Adenocarcinoma of Lung 57 12 74 44 71
Adenocarcinoma of Lung, Susceptibility to 57
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 71
Nonsmall Cell Adenocarcinoma 12
Lung Adenocarcinomas 15
Adenocarcinoma Lung 54
Lncr3 57

Classifications:



External Ids:

Disease Ontology 12 DOID:3910
OMIM® 57 612571
MeSH 44 D000077192
NCIt 50 C27745 C3512
SNOMED-CT 67 254626006
UMLS 71 C0152013 C1335060 C2675497

Summaries for Lung Cancer Susceptibility 3

GARD : 20 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and lung squamous cell carcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are MAPK Pathway and Bladder cancer. The drugs Endostar protein and Endostatins have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast.

Disease Ontology : 12 A lung non-small cell carcinoma that derives from epithelial cells of glandular origin.

Wikipedia : 74 Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 738)
# Related Disease Score Top Affiliating Genes
1 lung cancer 33.9 TUG1 ROS1 PACRG MIR31HG MALAT1 LINC-ROR
2 lung squamous cell carcinoma 33.0 TUG1 ROS1 MIR375 EGFR CCAT1 BRAF
3 high grade glioma 32.7 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
4 adenocarcinoma 32.1 ROS1 MALAT1 HNF1A-AS1 ERBB2 EGFR BRAF
5 small cell cancer of the lung 31.8 TUG1 MALAT1 HOTAIR EGFR
6 gastric cancer 31.8 TUG1 MIR31HG MALAT1 LINC-ROR HOTAIR HNF1A-AS1
7 hepatocellular carcinoma 31.8 TUG1 MALAT1 LINC-ROR HOTAIR HNF1A-AS1 GAS5
8 bladder cancer 31.7 TUG1 MIR31HG MALAT1 HOTAIR HNF1A-AS1 GAS5
9 thyroid carcinoma 31.6 MALAT1 HOTAIR GAS5 BRAF AFAP1-AS1
10 renal cell carcinoma, nonpapillary 31.6 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
11 glioblastoma 31.6 TUG1 ROS1 MALAT1 HOTAIR GAS5 ERBB2
12 esophageal cancer 31.6 MIR375 MALAT1 LINC-ROR HOTAIR GAS5 ERBB2
13 breast cancer 31.6 TUG1 MIR31HG MALAT1 LINC00472 LINC-ROR HOTAIR
14 large cell carcinoma 31.5 ROS1 ERBB2 EGFR
15 melanoma 31.5 MALAT1 LINC-ROR HOTAIR GAS5 ERBB2 EGFR
16 osteogenic sarcoma 31.5 TUG1 MALAT1 HOTAIR HNF1A-AS1 GAS5 FENDRR
17 glioma 31.5 MALAT1 HOTAIR GAS5 ERBB2 EGFR CYTOR
18 thyroid cancer, nonmedullary, 1 31.5 MALAT1 LINC-ROR HOTAIR BRAF
19 squamous cell carcinoma 31.4 TUG1 MALAT1 HOTAIR HNF1A-AS1 ERBB2 EGFR
20 cholangiocarcinoma 31.4 TUG1 ROS1 MALAT1 ERBB2 EGFR BRAF
21 retinitis pigmentosa 11 31.4 TUG1 HOTAIR GAS5 ERBB2 EGFR
22 nasopharyngeal carcinoma 31.3 MALAT1 LINC-ROR HOTAIR HNF1A-AS1 GAS5 EGFR
23 ovarian cancer 31.3 TUG1 MALAT1 LINC00472 LINC-ROR HOTAIR GAS5
24 oral squamous cell carcinoma 31.3 TUG1 MALAT1 HOTAIR EGFR CCAT1
25 intrahepatic cholangiocarcinoma 31.2 TUG1 ERBB2 EGFR CCAT1
26 colorectal cancer 31.2 TUG1 ROS1 MIR31HG MALAT1 LINC00472 LINC-ROR
27 kidney cancer 31.2 MALAT1 HOTAIR GAS5 EGFR
28 pancreatic cancer 31.2 TUG1 MIR375 MALAT1 LINC-ROR HOTAIR HNF1A-AS1
29 myeloma, multiple 31.2 TUG1 MALAT1 HOTAIR GAS5 ERBB2 EGFR
30 paronychia 31.1 ERBB2 EGFR
31 endometrial cancer 31.1 TUG1 LINC-ROR HOTAIR GAS5 ERBB2 EGFR
32 cervical cancer 31.1 TUG1 MIR31HG MALAT1 HOTAIR GAS5 ERBB2
33 colorectal adenocarcinoma 31.0 ERBB2 EGFR BRAF
34 leukemia, acute myeloid 30.9 TUG1 MALAT1 HOTAIR ERBB2 EGFR CCAT1
35 pancreatic ductal adenocarcinoma 30.9 MIR375 MIR31HG MALAT1 HOTAIR ERBB2 EGFR
36 skin melanoma 30.9 ROS1 ERBB2 EGFR BRAF
37 ovary adenocarcinoma 30.9 ERBB2 EGFR BRAF
38 bladder urothelial carcinoma 30.8 TUG1 MALAT1 HOTAIR GAS5 ERBB2 BRAF
39 endometrial adenocarcinoma 30.8 MALAT1 ERBB2 EGFR
40 suppression of tumorigenicity 12 30.8 ERBB2 EGFR BRAF
41 gastrointestinal stromal tumor 30.7 HOTAIR ERBB2 EGFR BRAF
42 gastric adenocarcinoma 30.7 ROS1 HOTAIR ERBB2 BRAF
43 ovarian epithelial cancer 30.6 MALAT1 HOTAIR CCAT1
44 glioma susceptibility 1 30.5 ERBB2 DGCR5 CYTOR
45 gastroesophageal junction adenocarcinoma 30.4 ERBB2 EGFR
46 renal cell carcinoma, papillary, 1 30.4 ERBB2 EGFR BRAF
47 mucinous lung adenocarcinoma 11.4
48 signet ring lung adenocarcinoma 11.4
49 lung papillary adenocarcinoma 11.2
50 tumor predisposition syndrome 11.2

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM®:

612571 (Updated 05-Mar-2021)

Drugs & Therapeutics for Lung Cancer Susceptibility 3

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostar protein Phase 4
2 Endostatins Phase 4 71581480
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Ipilimumab Approved Phase 3 477202-00-9
6
Ceritinib Approved Phase 3 1032900-25-6
7
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
10
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
11
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
12
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
15
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
16
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
19
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
20
Cobalamin Experimental Phase 3 13408-78-1 6857388
21 Mitogens Phase 3
22 Protective Agents Phase 3
23 Shark Cartilage Phase 3
24 2,2'-dithiodiethanesulfonic acid Phase 3
25 Pharmaceutical Solutions Phase 3
26 Antineoplastic Agents, Immunological Phase 3
27 Immunoglobulin G Phase 3
28 Endothelial Growth Factors Phase 3
29 Protein Kinase Inhibitors Phase 3
30 Liver Extracts Phase 3
31 Anesthetics Phase 3
32 Angiogenesis Inhibitors Phase 3
33 Folic Acid Antagonists Phase 3
34 Vitamin B Complex Phase 3
35 Folate Phase 3
36 Vitamin B9 Phase 3
37
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
38 Vitamin B 12 Phase 3
39 Vitamins Phase 3
40 Vitamin B12 Phase 3
41
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
42
Trametinib Approved Phase 1, Phase 2 871700-17-3 11707110
43
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
44
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
45
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
46
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
47
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Lenvatinib Approved, Investigational Phase 2 417716-92-8
50
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639

Interventional clinical trials:

(show top 50) (show all 234)
# Name Status NCT ID Phase Drugs
1 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
2 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
3 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
7 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
8 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Unknown status NCT02281708 Phase 3 vinorelbine plus cisplatin
9 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
10 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
11 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
12 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
13 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
14 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
15 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
16 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
17 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
18 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS Recruiting NCT03391869 Phase 3
19 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
20 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
21 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
22 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
23 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
24 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT03676192 Phase 3 CT-16;Avastin
25 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
26 Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study Not yet recruiting NCT04339218 Phase 3 Pembrolizumab;Pemetrexed;Carboplatin
27 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
28 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
29 Tyrosine-kinase Inhibitor (TKI) With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma Terminated NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
30 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
31 A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers Unknown status NCT01502202 Phase 2 Gefitinib;Placebo;Pemetrexed plusCIsplatin
32 An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations Unknown status NCT03486496 Phase 2 gefitinib;Berberine
33 A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Unknown status NCT02787447 Phase 2 TKI;Thymosin Alpha 1
34 Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study Unknown status NCT02621333 Phase 2 chemotherapy
35 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
36 A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Unknown status NCT03376737 Phase 2 Apatinib
37 Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial Unknown status NCT02951637 Phase 2 Pemetrexed plus carboplatin combined with gefitinib;Gefitinib
38 Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma Unknown status NCT02980991 Phase 2 Pemetrexed;Cisplatin
39 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab
40 Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Unknown status NCT01131429 Phase 2 Erlotinib;Docetaxel;Cisplatin;Docetaxel;Cisplatin;Erlotinib
41 Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. Unknown status NCT02704767 Phase 2 Apatinib;Tarceva;Placebo
42 A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma Unknown status NCT02146118 Phase 2 Erlotinib
43 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
44 Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial Unknown status NCT03728374 Phase 2 Anlotinib
45 An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation. Unknown status NCT02036359 Phase 2 erlotinib;docetaxel
46 Effectiveness and Safety of Adding Bevacizumab to Chemotherapy in Patients With Advanced Lung Adenocarcinoma With Stable Disease After 2 Cycles of First Line Combination Chemotherapy: a Multicenter, Prospective Cohort Study Unknown status NCT03240549 Phase 2 bevacizumab
47 A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation Unknown status NCT02264210 Phase 2 Icotinib
48 Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced Gradually Progressed NSCLC After First-line Icotinib: an Open-label, Single-arm, Multicenter Phase II Study Unknown status NCT03402464 Phase 2 Icotinib combined dihydroaremisinin
49 Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases Completed NCT01578668 Phase 2 erlotinib;pemetrexed;cisplatin;erlotinib
50 A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma Completed NCT01588704 Phase 2 Neoadjuvant Bevacizumab

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

40
Lung, Brain, Breast, Lymph Node, Thyroid, Bone, Endothelial

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 16434)
# Title Authors PMID Year
1
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 6 54 61
12719539 2003
2
Missense mutations of the BRAF gene in human lung adenocarcinoma. 61 54 6
12460919 2002
3
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 57
21725308 2011
4
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 57
19836008 2009
5
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 57
19151717 2009
6
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 57
18978787 2008
7
Lung cancer susceptibility locus at 5p15.33. 57
18978790 2008
8
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 6
15457249 2004
9
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
10
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 61 54
19854534 2010
11
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 54 61
20347035 2010
12
Comparative proteome analysis of human adenocarcinoma. 61 54
19381893 2010
13
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 61 54
20222723 2010
14
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 54 61
19589612 2010
15
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 54 61
20061363 2010
16
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 61 54
20150826 2010
17
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 61 54
19540014 2010
18
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 54 61
20154720 2010
19
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 54 61
20146241 2010
20
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 61 54
20350214 2010
21
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 54 61
19949890 2010
22
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 54 61
19556604 2010
23
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 54 61
20093391 2010
24
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 61 54
19130320 2010
25
EGFR mutations and the terminal respiratory unit. 54 61
20135199 2010
26
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 61 54
20052735 2010
27
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. 54 61
20007840 2010
28
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 61 54
20036260 2010
29
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. 61 54
19947923 2010
30
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 54 61
20007486 2010
31
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. 54 61
19875972 2010
32
COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. 54 61
19815609 2009
33
An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. 61 54
19899793 2009
34
A region within the 5'-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. 54 61
19887373 2009
35
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. 61 54
20003463 2009
36
ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. 61 54
20003391 2009
37
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 54 61
19887599 2009
38
Roles of pathologists in molecular targeted cancer therapy. 54 61
19891708 2009
39
Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. 61 54
19107575 2009
40
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. 54 61
19760750 2009
41
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. 54 61
19826035 2009
42
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. 54 61
19571039 2009
43
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 54 61
19826477 2009
44
Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. 54 61
19854132 2009
45
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. 54 61
19639960 2009
46
Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 54 61
19724887 2009
47
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 54 61
19724844 2009
48
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. 61 54
19685508 2009
49
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 54 61
19794967 2009
50
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. 61 54
19706809 2009

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 398)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic 560007 rs150036236 7:55259434-55259434 7:55191741-55191741
2 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Pathogenic 13968 rs121913366 7:140453145-140453145 7:140753345-140753345
3 PACRG NM_013988.2(PARK2):c.(8_8)_(171_171)+180544del Deletion Pathogenic 7049 6:162262766-162727661
4 ERBB2 NM_004448.3(ERBB2):c.2313_2324dup (p.Tyr772_Ala775dup) Duplication Pathogenic 13875 rs397516975 17:37880981-37880982 17:39724728-39724729
5 ERBB2 NM_004448.3(ERBB2):c.2328_2336dup (p.Val777_Ser779dup) Duplication Pathogenic 13876 rs587776805 17:37880998-37880999 17:39724745-39724746
6 ERBB2 NM_004448.3(ERBB2):c.2263_2264delinsCC (p.Leu755Pro) Indel Pathogenic 13877 rs121913469 17:37880219-37880220 17:39723966-39723967
7 ERBB2 NM_004448.3(ERBB2):c.2606T>G (p.Leu869Arg) SNV Pathogenic 431024 rs1131692237 17:37881414-37881414 17:39725161-39725161
8 EGFR NM_005228.5(EGFR):c.988G>A (p.Glu330Lys) SNV Pathogenic 560008 rs139429793 7:55223621-55223621 7:55155928-55155928
9 BRAF NM_001374258.1(BRAF):c.1517G>T (p.Gly506Val) SNV Pathogenic/Likely pathogenic 13967 rs121913351 7:140481411-140481411 7:140781611-140781611
10 ROS1 NM_002944.2(ROS1):c.6094G>A (p.Gly2032Arg) SNV Pathogenic/Likely pathogenic 376139 rs1057519788 6:117638347-117638347 6:117317184-117317184
11 SMAD4 NM_005359.6(SMAD4):c.1157G>C (p.Gly386Ala) SNV Likely pathogenic 376540 rs121912580 18:48593406-48593406 18:51067036-51067036
12 TP53 NM_000546.5(TP53):c.856G>C (p.Glu286Gln) SNV Likely pathogenic 376591 rs786201059 17:7577082-7577082 17:7673764-7673764
13 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys) SNV Likely pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
14 TP53 NM_001276697.2(TP53):c.-57T>C SNV Likely pathogenic 376565 rs1057519978 17:7578509-7578509 17:7675191-7675191
15 TP53 NM_000546.5(TP53):c.730G>A (p.Gly244Ser) SNV Likely pathogenic 376600 rs1057519989 17:7577551-7577551 17:7674233-7674233
16 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 17:7577114-7577114 17:7673796-7673796
17 BRAF NM_004333.6(BRAF):c.1786G>C (p.Gly596Arg) SNV Likely pathogenic 375943 rs121913361 7:140453149-140453149 7:140753349-140753349
18 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 17:7578407-7578407 17:7675089-7675089
19 B2M NM_004048.3(B2M):c.2T>C (p.Met1Thr) SNV Likely pathogenic 376371 rs1057519879 15:45003746-45003746 15:44711548-44711548
20 TP53 NM_000546.5(TP53):c.824G>C (p.Cys275Ser) SNV Likely pathogenic 376583 rs863224451 17:7577114-7577114 17:7673796-7673796
21 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 17:7578395-7578395 17:7675077-7675077
22 TP53 NM_000546.5(TP53):c.857A>C (p.Glu286Ala) SNV Likely pathogenic 376593 rs1057519985 17:7577081-7577081 17:7673763-7673763
23 TP53 NM_000546.5(TP53):c.643A>G (p.Ser215Gly) SNV Likely pathogenic 265337 rs886039484 17:7578206-7578206 17:7674888-7674888
24 DNMT3A NM_022552.5(DNMT3A):c.2645G>C (p.Arg882Pro) SNV Likely pathogenic 375880 rs147001633 2:25457242-25457242 2:25234373-25234373
25 TP53 NM_000546.5(TP53):c.647T>A (p.Val216Glu) SNV Likely pathogenic 376672 rs1057520004 17:7578202-7578202 17:7674884-7674884
26 TP53 NM_000546.5(TP53):c.809T>C (p.Phe270Ser) SNV Likely pathogenic 376594 rs1057519986 17:7577129-7577129 17:7673811-7673811
27 B2M NM_004048.3(B2M):c.1A>G (p.Met1Val) SNV Likely pathogenic 376369 rs1023835002 15:45003745-45003745 15:44711547-44711547
28 IDH1 NM_001282386.1(IDH1):c.394C>T (p.Arg132Cys) SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
29 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr) SNV Likely pathogenic 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
30 TP53 NM_000546.5(TP53):c.796G>C (p.Gly266Arg) SNV Likely pathogenic 376605 rs1057519990 17:7577142-7577142 17:7673824-7673824
31 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 17:7578272-7578272 17:7674954-7674954
32 KRAS NM_004985.5(KRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 45117 rs17851045 12:25380275-25380275 12:25227341-25227341
33 TP53 NM_000546.5(TP53):c.526T>A (p.Cys176Ser) SNV Likely pathogenic 376570 rs967461896 17:7578404-7578404 17:7675086-7675086
34 CTNNB1 NM_001904.4(CTNNB1):c.98C>G (p.Ser33Cys) SNV Likely pathogenic 376231 rs121913400 3:41266101-41266101 3:41224610-41224610
35 TP53 NM_000546.5(TP53):c.821T>G (p.Val274Gly) SNV Likely pathogenic 376676 rs1057520006 17:7577117-7577117 17:7673799-7673799
36 TP53 NM_000546.5(TP53):c.374C>A (p.Thr125Lys) SNV Likely pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
37 EGFR NM_005228.5(EGFR):c.2582T>A (p.Leu861Gln) SNV Likely pathogenic 163380 rs121913444 7:55259524-55259524 7:55191831-55191831
38 FGFR2 NM_000141.5(FGFR2):c.1642A>C (p.Ile548Leu) SNV Likely pathogenic 376433 rs1057519901 10:123258039-123258039 10:121498525-121498525
39 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp) SNV Likely pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
40 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr) SNV Likely pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
41 TP53 NM_000546.5(TP53):c.613T>G (p.Tyr205Asp) SNV Likely pathogenic 376686 rs1057520008 17:7578236-7578236 17:7674918-7674918
42 TP53 NM_000546.5(TP53):c.715A>G (p.Asn239Asp) SNV Likely pathogenic 234036 rs876660807 17:7577566-7577566 17:7674248-7674248
43 TP53 NM_000546.5(TP53):c.726C>G (p.Cys242Trp) SNV Likely pathogenic 376580 rs375874539 17:7577555-7577555 17:7674237-7674237
44 TP53 NM_000546.5(TP53):c.536A>G (p.His179Arg) SNV Likely pathogenic 376606 rs1057519991 17:7578394-7578394 17:7675076-7675076
45 SMAD4 NM_005359.6(SMAD4):c.1156G>A (p.Gly386Ser) SNV Likely pathogenic 376538 rs1057519962 18:48593405-48593405 18:51067035-51067035
46 TP53 NM_000546.5(TP53):c.614A>T (p.Tyr205Phe) SNV Likely pathogenic 376682 rs1057520007 17:7578235-7578235 17:7674917-7674917
47 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro) SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242
48 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
49 BRAF NM_004333.6(BRAF):c.1742A>C (p.Asn581Thr) SNV Likely pathogenic 376376 rs121913370 7:140453193-140453193 7:140753393-140753393
50 TP53 NM_000546.5(TP53):c.797G>T (p.Gly266Val) SNV Likely pathogenic 233303 rs193920774 17:7577141-7577141 17:7673823-7673823

Cosmic variations for Lung Cancer Susceptibility 3:

9 (show top 50) (show all 35823)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 30
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 30
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 30
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 30
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 30
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 30
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 30
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 30
15 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 30
16 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 30
17 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 30
18 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 30
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 30
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 30
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 30
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 30
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 30
24 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 30
25 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 30
26 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 30
27 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 30
28 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 30
29 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 30
30 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 30
31 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 30
32 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 30
33 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 30
34 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 30
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 30
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 30
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 30
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 30
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 30
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 30
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 30
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 30
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 30
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 30
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 30
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 30
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 30
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 30
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 30
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 30

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE1 Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification NAXE Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification NECTIN4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C1, slow skeletal and cardiac type Lung - 5.28 0.000
2 COL11A1 collagen type XI alpha 1 chain Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end-product specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4 Lung - 4.32 0.000
8 CDH3 cadherin 3 Lung + 4.31 0.000
9 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3 member B Lung - 4.18 0.000
12 FCN3 ficolin 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen type X alpha 1 chain Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 Lung - 3.59 0.000
22 TMPRSS4 transmembrane serine protease 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibril associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP binding cassette subfamily C member 3 Lung + 3.47 0.000
26 TOP2A DNA topoisomerase II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase 4 Lung - 3.38 0.000
29 CYP4B1 cytochrome P450 family 4 subfamily B member 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 Lung + 3.29 0.000
32 NEK2 NIMA related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP binding cassette subfamily A member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin family 1A member 1 Lung - 3.17 0.000
38 VEGFD vascular endothelial growth factor D Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan gamma Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen type I alpha 1 chain Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.43 ERBB2 EGFR BRAF
2 10.66 ERBB2 EGFR BRAF
3 10.03 LINC-ROR HOTAIR

GO Terms for Lung Cancer Susceptibility 3

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 ROS1 ERBB2 EGFR
2 positive regulation of kinase activity GO:0033674 9.43 ROS1 ERBB2 EGFR
3 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ROS1 ERBB2 EGFR BRAF
4 negative regulation of ERBB signaling pathway GO:1901185 9.16 ERBB2 EGFR
5 regulation of ERK1 and ERK2 cascade GO:0070372 8.8 ROS1 ERBB2 EGFR

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.33 ROS1 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 ROS1 ERBB2 EGFR
3 protein tyrosine kinase activity GO:0004713 8.92 ROS1 ERBB2 EGFR BRAF

Sources for Lung Cancer Susceptibility 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....